NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

TerminatedPhase 2

Sponsor: Sanofi

Conditions: Ankylosing Spondylitis

Interventions: Sarilumab

Countries: United States, Australia, Austria, Belgium, Canada, Czechia, France, Hungary

Primary Objective: * To assess the long term safety of Sarilumab (SAR153191/REGN88) in participants with ankylosing spondylitis (AS) Secondary Objective: * To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in participants with AS

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion criteria:

* Participant with AS who participated and completed 12-week treatment in study DRI11073-NCT01061723.

Exclusion criteria:

* Adverse event(s) having lead to treatment discontinuation in the DRI11073 study;
* Event or laboratory abnormality observed at the last treatment visit of DRI11073 study that would have adversely affected participation of the participant in this study as per investigator judgment.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Locations (12)

Bridgewater, New Jersey, United States
Macquarie Park, New South Wales, Australia
Vienna, Austria
Diegem, Belgium
Laval, Canada
Prague, Czechia
Paris, France
Budapest, Hungary
Vilnius, Lithuania
Gouda, Netherlands
Warsaw, Poland
Barcelona, Spain